If you missed the 10X call on VKTX: Then analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 75usd strike price Calls with an expiration date of 2024-5-17, for a premium of approximately $2.57. If these options prove to be profitable prior to the earnings release,...
After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend. **Potential Scenarios:** **Scenario 1: Triangular Consolidation (Orange)** ATAI may undergo consolidation...
Gilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at...
Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is...
Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation...
TSXV:NRX Nurexone Biologic leading biotech plays in 2024 with several recent developments from newly uplisting on the OTC, leasing agreement until 2028 of a state-of-the-art facility on a University campus in Israel to beginning clinical trials shortly.
Showcasing the recent developments of TSXV:NRX , will be upgrading on the OTC very soon which should help the volume. Currently holding the 200MA.
VINC was a penny stock and is now in the near penny category as this biotech stock has had a great run in the past 10 days. On the 30 minute chart, 225 shares are bought at low prices and 125 shares are sold for profit with 100 shares still running as the momentum slows. Overall, the trades where profitable averaging 12% daily in an average trade of 4.5...
Wuxi Biologics (2269): HKEX:2269 Wuxi Biologics, a Chinese biotech research company listed on the Hong Kong Stock Exchange, presents a complex investment scenario. It's crucial to note we're dealing with the Hong Kong Dollar, not the US dollar. The comprehensive analysis on the weekly chart suggests that since June 2021, the company has been undergoing a...
VINC went from 1.5 to 3.0 in less than three hours with 12X relative volume in the afternoon after a month of a slow climb from a news release that really did not amount to much. Insiders are 25% of the shareholders and that may be the story here. This could be manipulation at its finest. I have to wonder how many insiders bought how many shares and when the...
Positive news on phase 3 trials. Possible US food & drug admin application next year 2025 8.5 times the usual 20 daily volume average. Red to green reversal. This all points towards likely higher prices. If their application next year gets approved expect a monster move. Investors will likely try to front run this.
Quantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest The stock is...
At some point there will be a boom biotechnology stocks. They haven't done much in the past ten years. I believe IBB will pass 250 within the decade. However, if the market remains stable, without any 20%+ corrections, I think IBB hits 250 to 300 in the next year
📊 Analysis NASDAQ:BPMC : Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers. Market Prospects: Positive market response to Ayvakit's unique clinical profile. CEO's Confidence: CEO's confidence in the company's future contributes to its momentum. 📈 Bullish Sentiment: Entry Range: Suggested entry...
NRIX , on the 15 minute chart is experiencing increase volatility and volume now two days out from its earnings report. It printed a "big ass" green engulfing candle to finish the week. The MACD with zero lag shows a bullish inflection in the lines On the daily chart, price fell about 25% in 2023. earnings have been both line beats but the negative cash flow...
On the weekly chart a LABU / LABD ratio is plotted with anchored VWAP bands and a volume profile overlaid. I wanted to analyze this to affirm the highest of prospects for the Biotechnology sector for 2024. LABU is triple leveraged Up while LABD is the inverse Down. A good unleveraged biotech ETF is XBI. The chart shows LABU in a VWAP band and breakout ...
XBI, the S&Ps Biotech ETF has been ranging nicely just below a major pivot that has acted as resistance for over two years. Bounced off the 20 EMA on the daily and made a beautiful candle on Friday. Anything that happens below $95 must be taken with a grain of salt, but it looks like it wants to breakout and flip that resistance pivot to support.
Neurocrine Biosciences, a mid cap pharmaceutical firm is up for earnings on February 7th. Investor and trader interest seems to be moderately increasing in the past week. The combined MACD / RSI indicator is bullish. This looks good for a longtrade to be taken in the premarket before 7:45 AM as earnings report at 8:00